AzTrials
AzTrials

Dysfunctional WorryNCT04341922

A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic

A study testing Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic in people with Dysfunctional Worry, run by Karolinska Institutet at 1 site in Sweden.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate if a brief online-delivered cognitive-behavioral intervention can reduce the degree of dysfunctional worry related to the Covid-19 pandemic, compared to a wait-list control condition. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Dysfunctional Worry
What is being tested?
Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic
Could I receive a placebo?
No, everyone receives an active treatment
How many people
670 participants
Where
1 siteSweden
Study dates
9 May 2020to 10 Sep 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The following 2 criteria must be met:
  • Worrying about Covid-19 and its possible consequences (e.g. risk of getting ill, fear of death, economy, family, etc.) every day, often several times a day
  • The worry about Covid-19 is perceived as difficult to control
  • In addition, at least one of the following negative consequences of worrying:
  • The worry about Covid-19 takes so much time and energy that it is difficult to concentrate on anything else (work, family, hobbies, etc.)
  • Trouble sleeping due to Covid-19 worries
Show all 12Show fewer
  • Constantly checking the news and social media to follow developments about Covid-19
  • Marked loss of work productivity due to worries about Covid-19
  • Difficulties finding joy in everyday situations because of worry about Covid-19
  • ≥ 18 years of age
  • Resident in Sweden
  • Daily access to a computer or other device with internet connection

Who cannot join

  • Non Swedish speaking
  • Severe depression, defined as >28 points on the MADRS-S
  • Suicidal risk defined as 5 points or above on item 9 on the MADRS-S
  • Family member in the same household who is included in the study

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Karolinska Institutet

    Stockholm, 17177

Other trials in Sweden

About this study

Official title: Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial

The purpose of this study is to investigate if a brief online-delivered cognitive-behavioral intervention can reduce the degree of dysfunctional worry related to the Covid-19 pandemic, compared to a wait-list control condition.

Read the detailed description

Worries about the immediate and long-term consequences of the ongoing Covid-19 pandemic are largely justified in the current climate of uncertainty. However, dysfunctional worry, that is, pervasive worry that is disproportionate in its intensity or duration, and that significantly interferes with every-day problem-solving or goal-driven behavior, is clearly counterproductive. Research has also indicated that repeated media exposure to a community crisis can lead to increased anxiety and heightened stress responses, that can give a downstream effect on health, and misplaced health-protective and help-seeking behaviors which, in turn, may overburden health care facilities. There is an urgent need to develop a brief, scalable intervention to target such dysfunctional worry in the general population.

The current randomized controlled trial will evaluate the feasibility and efficacy of a brief online-delivered cognitive behavioral intervention designed to target dysfunctional worry related to the Covid-19 pandemic. 670 individuals are randomized to intervention or to waiting-list. The hypothesis is that the brief self-guided intervention will show significant within-group reductions in self-rated worry from baseline (week 0) to post-treatment (week 3), and that these improvements will be larger than those seen in the wait-list control group. The wait-list group will be crossed over to receive the intervention after three weeks (post-treatment). All participants will be followed-up one month and one year after the end of the intervention.

Being tested
Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic
Keywords
Covid-19, internet-delivered, cognitive behavioral intervention
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemicBehavioural

    The intervention focuses on 1) teaching participants how to discriminate between functional and dysfunctional worry (what are solvable problems vs. what is worry, i.e. unsolvable thoughts?) 2) providing participants with skills to solve functional worry topics (e.g. set time and make a workable plan to be prepared for possible negative outcomes [e.g. becoming unemployed]), 3) helping participants to reduce unhelpful behaviors that may reinforce worry (e.g., limit excessive news consumption, refrain from assurance seeking behaviors), 4) providing participants with skills to approach dysfunctional worry (e.g., not engage in worrisome thoughts, just leave them), and 5) increase the behavioral repertoire (take walks, engage in activities that promote health without putting oneself at risk to become infected).

Study groups in NCT04341922
Study groupRoleWhat they receive
Intervention: Online Cognitive-Behavioral interventionExperimentalThe three-week intervention is a structured self-guided program without therapist support, administered via a secure web platform and organized in five brief modules. The treatment is provided through an encrypted online platform (login through BankID and double authentication) provided by the eHealth Core facility at Karolinska Institutet
Receives: Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic
Wait-listNo interventionThe wait-list controlled composes of no intervention for three weeks. Participants randomized to the wait-list group will be crossed over to receive the Online Cognitive-Behavioral intervention after three weeks (post-treatment).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. • Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)

    A 7-item self-rated scale to assess symtom severity of worry. Total score ranging from 0 to 21. Effects will be expressed as the change from baseline to last post-treatment value (Week 0-Week 3) period. Effects will also be assessed at one month and one year post-treatment.

    Measured: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.

Secondary outcomes (7)
  1. Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S)

    A 9-item self-rated scale to assess symtoms of depression.Total score ranging from 0 to 54.

    Measured: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.

  2. Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)

    A 5-item self-rated scale adapted to measure impact of the Covid-19 pandemic on work and social functioning. Total score ranging from 0 to 40.

    Measured: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.

  3. Insomnia Severity Index (ISI)

    A 7-item self-rated scale to asess severity of insomnia symtoms. Total score ranging from 0 to 28.

    Measured: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.

  4. Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)

    A self-rated scale to assess Coronavirus/covid-19 health/exposure status, life changes, changes in daily behaviors, impact on emotions/worries, changes in media use past two weeks and changes in substance use due to coronavirus/covid-19 crisis. The scale has bees translated to Swedish and adopted to a Swedish context.

    Measured: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.

  5. Intolerance of uncertainty Scale (IUS)

    A 12-item self-rated scale to assess intolerance of uncertainty. Total score ranging from 12 to 60.

    Measured: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.

  6. Patient Satisfaction Questionnaire (PSQ)

    A self-rated scale to assess treamtent satisfaction.

    Measured: Post treatment (week 3)

  7. Adverse events (AE)

    A self-rated questionnaire with free text options to assess adverse events du to the intervention.

    Measured: Post treatment (week 3)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Apr 2020
  2. Study start9 May 2020
  3. Primary completion20 Aug 2020
  4. Study completion10 Sep 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
670 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04341922
Sponsor's protocol ID
2020-01719
Status last verified
Oct 2020
First submitted
7 Apr 2020
Last updated
19 Oct 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Wahlund T, Mataix-Cols D, Olofsdotter Lauri K, de Schipper E, Ljotsson B, Aspvall K, Andersson E. Brief Online Cognitive Behavioural Intervention for Dysfunctional Worry Related to the COVID-19 Pandemic: A Randomised Controlled Trial. Psychother Psychosom. 2021;90(3):191-199. doi: 10.1159/000512843. Epub 2020 Nov 19.

    PubMed 33212440

Questions about this trial

What is this clinical trial studying?

A study testing Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic in people with Dysfunctional Worry, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

• Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7) (time frame: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04341922, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2020; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in